PPMD's Blog – April 2013 Archive (6)

Report from MDA's Scientific Conference 2013

PPMD President Pat Furlong and Vice President of Research Sharon Hesterlee are attending MDA’s Scientific Conference this week in Washington, D.C. Most of what was presented are results that were previously announced. However, there were some interesting presentations, as well as, results worth repeating, that we wanted to share. Sharon and Pat will continue to blog from the conference:

 

From Pat Furlong

Interview with Thomas Voit

While the content…

Continue

Added by PPMD on April 24, 2013 at 10:00am — 6 Comments

Continued Access to Drisapersen for Patients Completing the US Ph IIb 48-week study

Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :

The purpose of this communication is provide an update to you, as you have requested, on GSK’s plans for providing the option of continued access to drisapersen for boys completing the US Ph IIb 48 week study (DMD114876)…

Continue

Added by PPMD on April 24, 2013 at 9:30am — No Comments

Duchenne: An Intergenerational Issue

Guest post by Gail D. McVicker, Grandmother of Jake (10) and Ryan (6) - Pennsylvania

Duchenne: An Intergenerational Issue



Five years ago, I did not know the world of Duchenne muscular dystrophy existed. Before my young grandsons were officially diagnosed in 2008, my daughter told me that some genetic…

Continue

Added by PPMD on April 17, 2013 at 2:49pm — 2 Comments

Pipeline Update: Drisapersen, GSK Report from Cold Spring Harbor Conference

PPMD received the email update below from Hans Schikan at Prosensa:

Dear all,

Today, at the Cold Spring Harbor conference in the US, Dr John Kraus of GSK gave an excellent presentation on the outcome of the 117 (DEMAND II) clinical trial. The primary endpoint in this exploratory study was met and a statistically and clinically meaningful difference of 35 meters in the six-minute walk test between the continuous dosing regimen of 6mg/kg per week and placebo was…

Continue

Added by PPMD on April 12, 2013 at 11:39am — No Comments

Pipeline Update: Drisapersen, GSK

Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :

To keep you updated on the progress of the drisapersen (previously GSK2402968) clinical development program, as you have requested, I am writing to inform you that the results of the GSK Phase IIb study investigating drisapersen as…

Continue

Added by PPMD on April 5, 2013 at 10:51am — No Comments

Living Duchenne: Silence and Noise

Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.



Living Duchenne: Silence

 

One interesting thing about silence is listening to…

Continue

Added by PPMD on April 4, 2013 at 11:30pm — No Comments

Monthly Archives

2018

2017

2016

2015

2014

2013

2012

2011

2010

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service